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Background: Nevirapine is an important component of paediatric combination HIV therapy. Adequate drug
exposure is necessary in order to achieve long-lasting viral suppression.
Objectives: To study the influence of age, drug dose and formulation type, nutritional status and CYP2B6
516G.T polymorphism on blood concentrations of nevirapine in children treated with generic antiretroviral
drugs.
Methods: A multicentre study was conducted at four sites in India. HIV-infected children receiving generic
nevirapine-based fixed-dose combinations were recruited. Trough and 2 h nevirapine plasma concentrations
were determined by HPLC. Characterization of the CYP2B6 gene polymorphism was performed using direct
sequencing. Clinical and nutritional status was recorded. Groups were compared using the Mann–Whitney
U-test and multivariable logistic regression analysis was performed to identify factors contributing to low
drug levels.
Results: Ninety-four children of median age 78 months were studied; 60% were undernourished or stunted.
Stunted children had a significantly lower 2 h nevirapine concentration compared with non-stunted children
(P,0.05); there were no significant differences in trough concentrations between different nutritional
groups. Nevirapine levels were significantly higher in children with TT compared with GG and GT CYP2B6 geno-
types (P,0.01). Children ≤3 years had a 3.2 (95% confidence interval 1.07–9.45) times higher risk of having
sub-therapeutic nevirapine concentrations.
Conclusions: Nevirapine blood concentrations are affected by many factors, most notably age ≤3 years; a com-
bination of young age, stunting and CYP2B6 GG or GT genotype could potentially result in sub-therapeutic nevir-
apine concentrations. Dosing recommendations for children should be reviewed in the light of these findings.
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Introduction
There are an estimated 2.5 million HIV-infected children
worldwide, most of them living in countries with high rates
of poverty and malnutrition. While access to antiretroviral
treatment (ART) for adults has increased dramatically since the
WHO’s 3 by 5 initiative, that of HIV-infected children has lagged
behind. This is due partly to lack of diagnostic facilities and
partly to lack of affordable and appropriate antiretroviral
formulations.
India rolled out its free ART programme in April 2004 scaling up
rapidly: .350000 patients had been initiated on treatment,
including 21000 children, as of August 2010.1 In 2006, the
WHO published guidelines for the treatment of children in
resource-poor settings and these were updated in 2008.2 Specifi-
cally, the dose of nevirapine was revised to a higher range of 300–
400 mg/m2/day, based on experience and emerging data that
children required a higher mg/kg dose of nevirapine.3 In India,
ART was initially provided using adult formulations; paediatric
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formulations were made available by the National AIDS Control
Organisation (NACO) at government ART centres from November
2006. These specially formulated paediatric generic drugs are
available as fixed-dose combinations (FDCs), consisting of
stavudine with lamivudine and nevirapine formulated in two
different ratios (6:30:50 and 10:40:70 mg). A weight-based
dosing card has been developed for ease of use in the ART
centres, which aims to provide the correct dose of all three
drugs to children in a simplified way using weight bands (Table 1).4
It has been suggested that adult FDCs, while suitable for older
children, are not appropriate for young children.5 Not many
studies have specifically examined the bioavailability of paedia-
tric FDCs5,6 and none has been performed in India. The aim of
this study was to examine the influence of age, sex, drug dose,
type of formulation, nutritional status and CYP2B6 516G.T
polymorphism on the steady-state plasma concentrations of
nevirapine in HIV-infected children receiving treatment with
generic adult or paediatric antiretroviral formulations in India.
Methods
Patients
HIV-infected children (6 months–12 years) receiving ART for at least
15 days at the Government Rajaji Hospital (Madurai), BJ Wadia Hospital
(Mumbai), Government Hospital of Thoracic Medicine (Chennai) and
Kilpauk Medical College and Hospital (Chennai) were recruited to the
study. None was on concurrent rifampicin-containing anti-tuberculosis
treatment. The study was conducted at the outpatient clinics of the hos-
pitals, after obtaining approval from the institutional ethics committees
of the individual study sites, and written informed consent from
parent/guardian. Blood was drawn when the child came in to the clinic
(trough concentration) and 2 h after directly observed administration of
antiretroviral drugs. CD4 cell counts and viral load values were noted
from the patients’ records wherever available.
Treatment
All children were receiving a generically formulated combination of lami-
vudine and nevirapine with stavudine. Dosing was based on body weight
bands as per NACO guidelines (Table 1). Further, while the majority of
children received either one of two paediatric formulations, 39 children
received an adult formulation. The parent or guardian was questioned
regarding adherence and whether the child had been administered the
previous night’s dose.
Assessment of nutritional status
Height (to the nearest cm) and weight (to the nearest 0.1 kg) were
measured. The Z scores for weight and height were computed based
on the child’s age and gender using the EPI-NUT component of the
EPI-INFO 2002 software package (version 3.4.3) from the CDC [based
on the National Centre for Health Statistics (NCHS) reference median
values]. The Global Database on Child Growth and Malnutrition rec-
ommends a cut-off Z score lower than 22 to classify low weight-for-age
(WAZ) (underweight), low height-for-age (HAZ) (stunting) and low
weight-for-height (WHZ) (wasting) as moderate and a Z score lower
than 23 SD to define severe under-nutrition.7 A Z score lower than 22
indicates that a child’s HAZ, WAZ or WHZ is 2 SD below the age- and
gender-specific median for the normal population.
Drug estimations
Plasma concentration of nevirapine was determined by a validated HPLC
(Shimadzu Corporation, Kyoto, Japan) method with UV detection.8
3-Isobutyl 1-methyl xanthine was used as the internal standard. Cali-
bration curves using known concentrations of nevirapine (0.05–10 mg/
mL) were constructed on each assay day. Inter-day variations of the cali-
bration curve standards ranged from 98% to 104% with an accuracy of
101%. Unknown concentrations were derived from linear regression
analysis of the peak height ratios (analyte/internal standard) versus con-
centration curve.
Genotyping of CYP2B6 G516T
Genetic characterization of the CYP2B6 gene was performed using
genomic DNA extracted from whole blood. A 204 bp fragment in exon
4 of the CYP2B6 gene containing the target site (position 516) was ampli-
fied by a single round of PCR, using the following oligonucleotide
primers:9 CYP2B6 forward primer (5′-CTTGACCTGCTGCTTCTTCC-3′); and
CYP2B6 reverse primer (5′-TCCCTCTCCGTCTCCCTG-3′). The amplicon was
directly sequenced using a 3100 Avant Genetic Analyzer (Applied Biosys-
tems, USA).
Table 1. NACO revised paediatric dosing schedule (2007)
Weight (kg) Type of tablet
No. of tablets daily
Nevirapine daily
dose (mg)
Nevirapine daily
dose mg/m2
Nevirapine daily
dose mg/kgAM PM
3–4.9 stavudine 6+ lamivudine
30+nevirapine 50
1 1 100 189–426 5–20
5–5.9 1.5 1 125
6–9.9 1.5 1.5 150
10–11.9 2 2 200
12–13.9 stavudine 10+ lamivudine
40+nevirapine 70
1.5 1.5 210 83–445 3.3–18.7
14–16.9 2 1.5 245
17–19.9 2 2 280
20–24.9 stavudine 30+ lamivudine
150+nevirapine 200
1 0.5 300 222–750 4.8–22.3
≥25.0 1 1 400
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Statistical evaluation
Analysis of data was performed using SPSS version 14. Comparison of
nevirapine concentrations between different groups of children was per-
formed using the Mann–Whitney U-test. Multiple group comparisons
were performed using the Kruskal–Wallis test. A x2 test was used to
test the difference between the proportions of children with sub-
therapeutic nevirapine trough concentrations (,3.0 mg/mL) receiving ,
and ≥300 mg/m2/day, and with different grades of malnutrition. Multiple
logistic regression analysis by a backward elimination method was
carried out to identify the contribution of various factors resulting in sub-
therapeutic nevirapine trough concentrations. A P value of ≤0.05 was
considered statistically significant.
Results
Ninety-four HIV-infected children participated in the study
(patient characteristics given in Table 2). Trough and 2 h nevirapine
concentrations were available for 88 and 87 children, respectively
(a few children had only one sample collected). The majority of the
children were malnourished with 37% and 20% moderately and
severely underweight, and 21% and 40% moderately and severely
stunted, respectively (sub-groups combined for analysis). The daily
prescribed nevirapine dose in mg/m2/day was significantly lower
in the formulation with 70 mg of nevirapine compared with the
other formulations with 50 and 200 mg of nevirapine. However,
the type of formulation used did not have any impact on peak or
trough concentrations.
Table 3 shows plasma nevirapine in children grouped based
on age, sex, dose, formulation, HAZ and WAZ. Stunted children
had a significantly lower 2 h nevirapine concentration compared
with non-stunted children (P,0.05), but trough concentrations
were not different. Children ≤3 years of age had both lower
trough and 2 h nevirapine concentrations compared with those
.3 years; the differences were statistically significant (P,0.05).
Though a higher proportion of children ≤3 years had sub-
therapeutic levels compared with those .3 years, this was not
statistically significant (59% versus 31%, respectively). On multi-
variable logistic regression, among the variables studied such as
age, nevirapine dose in mg/m2/day, HAZ and WAZ, age was the
only factor found to be significantly associated with sub-
therapeutic nevirapine trough concentrations of ,3 mg/mL
(odds ratio 3.2; 95% confidence interval 1.07–9.45; P,0.05).
CYP2B6 516G.T genotyping was performed in 28 children in
whom adequate blood samples were available; 11, 12 and 5
had GG, GT and TT genotype, respectively. The demographic
details and nevirapine concentrations of these 28 children are
shown in Table 4. No significant association was observed
between the genotypes and age or nevirapine dose, though chil-
dren in the GG and GT groups were apparently younger and more
malnourished. Trough and 2 h nevirapine concentrations were
significantly higher in the children with TT genotype compared
Table 2. Demographic characteristics of study participants (n¼94)
Variables Median (range)
Age (months) 78.1 (9.6–184.5)
Weight (kg) 16.0 (5.7–36.4)
WAZ score 22.1 (24.9–2.2)
Height (cm) 109.0 (64.0–156.8)
HAZ score 22.6 (26.6–3.8)
WHZ score 20.4 (24.6–10.0)
Body mass index (kg/m2) 14.5 (8.8–20.2)
Body surface area (m2) 0.7 (0.3–1.3)
Duration of ART (months) 17 (1–54)
CD4, % 12 (3–30)
Daily prescribed NVP dose (mg/m2/day), d4T:3TC:NVP
6:30:50 294.7 (178.6–476.2)
10:40:70 280.0 (83.3–567.5)a
30:150:200 353.1 (222.2–750.0)
Daily prescribed NVP dose (mg/m2/day)
≤3.0 years 312.5 (178.6–567.5)
.3.0 years 318.2 (83.3–750.0)
Daily prescribed NVP dose (mg/kg/day), d4T:3TC:NVP
6:30:50 13.6 (5.0–26.3)
10:40:70 13.5 (3.3–25.9)
30:150:200 14.2 (8.7–18.8)
d4T, stavudine; NVP, nevirapine; 3TC, lamivudine.
aP,0.05.
Table 3. Plasma nevirapine concentrations (median and range) in
different groups of children
Groups n Trough (mg/mL) n 2 h (mg/mL)
Sex
female 41 3.6 (0.6–12.6) 39 5.0 (1.5–16.3)
male 47 3.7 (0.1–10.1) 48 6.0 (1.6–18.9)
Dose
,300 mg/m2/day 40 3.3 (1.3–10.9) 40 5.3 (2.1–18.9)
≥300 mg/m2/day 48 4.1 (0.1–12.6) 47 6.2 (1.5–16.3)
Drug formulations,
d4T:3TC:NVP
6:30:50 24 3.5 (0.1–10.9) 22 5.2 (1.5–13.5)
10:40:70 25 3.3 (1.2–10.1) 27 5.3 (1.6–18.9)
30:150:200 39 4.5 (0.6–12.6) 38 6.1 (1.6–16.3)
HAZ score
stunted (,22 HAZ) 55 3.6 (0.6–12.6) 55 5.3 (1.6–14.3)a
normal 33 3.9 (0.1–10.0) 32 6.1 (1.5–18.9)
WAZ score
underweight (,22 WAZ) 51 3.7 (0.6–12.6) 53 5.6 (1.6–18.9)
normal 37 3.2 (0.1–10.9) 34 5.6 (1.5–16.3)
Age
≤3 years 17 2.5 (0.1–10.9)a 14 4.2 (1.5–13.5)a
.3 years 71 4.0 (0.6–12.6) 73 5.7 (1.6–18.9)
aP,0.05.
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with GG and GT genotypes (P,0.01). None of the children in this
study had any nevirapine-associated toxicity.
Overall, 32 children (35%) had sub-therapeutic nevirapine
trough concentrations; of those, 10 children were ≤3 years.
CYP2B6 516G.T genotype status was known for only seven chil-
dren, of whom four and three belonged to GG and GT genotypes,
respectively. Post-ART viral load values were available for 10 of
these 32 children; four had detectable viral load after
6 months of ART. Post-ART viral load was also available for nine
of the remaining children with adequate blood concentrations;
two of these nine children had a detectable viral load; this differ-
ence (4/10 versus 2/9) was not significant.
Discussion
In this cohort of children being treated with generic paediatric
FDCs in India, a substantial proportion (35%) had sub-
therapeutic nevirapine trough levels (,3 mg/mL), and this was
more pronounced in young children. Of the factors investigated,
age was the major predictor of low nevirapine levels, confirming
previous reports.5,6 However, most previous studies were in chil-
dren receiving fractions of adult FDC tablets and there has been
limited information on children receiving paediatric formulations
so far. While low blood drug concentrations could be due to poor
bioavailability, poor compliance, low dose or an increase in
metabolism, the first three factors are unlikely in this case.
Metabolism of drugs varies with age but the relationship of
age and drug dosage is not linear. In general, newborns and
infants ,1 year metabolize drugs more slowly, while for children
.1 year of age, significantly higher weight-corrected doses com-
pared with adults are needed for drugs eliminated by the cyto-
chrome P450 (CYP) isozymes CYP1A2, CYP2C9 and CYP3A4
(including nevirapine). In contrast, weight-corrected doses for
drugs eliminated by renal excretion or metabolism by CYP2C19,
CYP2D6, N-acetyltransferase and UDP glucuronosyltransferase
in children are similar to those in adults.10,11 Our finding of
younger children being at higher risk of having sub-therapeutic
plasma nevirapine trough concentrations (in spite of using
nevirapine doses in the recommended dosing range of 300–
400 mg/m2) is similar to that reported by Poerksen et al.12
They reported that while using adult Triomune 30 tablets, the
majority of children achieved a therapeutic nevirapine concen-
tration; however, treatment was suboptimal in younger children
receiving dosages of less than half-tablets twice daily. Ellis et al.5
Table 4. Demographic details and plasma nevirapine concentrations among children with different genotypes
of CYP2B6 516G.T polymorphism
Variables
Median (range)
GG (n¼11) GT (n¼12) TT (n¼5)
Age (months) 77.7 (16.4–140.8) 80.1 (48.5–134.1) 99.9 (63.3–127.3)
Weight (kg) 17.4 (7.5–23.5) 17.5 (14.0–27.0) 16.0 (11.0–28.0)
WAZ score 22.4 (24.0 to 21.5) 22.0 (23.0–0.4) 21.8 (23.8 to 21.2)
Height (cm) 104.0 (72.0–136.0) 109.5 (95.0–131.0) 113.0 (97.0–134.0)
HAZ score 22.7 (24.1 to 21.3) 22.0 (24.6–2.0) 21.7 (23.2–1.2)
WHZ score 21.2 (22.7–10.0) 20.5 (24.6–10.0) 21.3 (23.0–10.0)
Body mass index (kg/m2) 13.9 (12.0–16.1) 14.5 (9.1–17.1) 13.7 (11.7–15.6)
Body surface area (m2) 0.7 (0.4–0.9) 0.7 (0.6–1.0) 0.7 (0.6–1.0)
Duration of ART (months) 14 (1–54) 14 (1–54) 13.5 (1–33)
CD4, % 12.5 (5–23) 18 (5–27) 7 (3–11)
Daily prescribed NVP dose (mg/m2/day), d4T:3TC:NVP
6:30:50 279 (195–320) 270a 293a
10:40:70 314 (302–327) 280 (83–400) 342 (239–446)
30:150:200 238 (222–430) 299 (233–388) 375 (361–388)
Daily prescribed NVP dose (mg/kg/day), d4T:3TC:NVP
6:30:50 15.6 (13.3–16.0) 11.4a 13.0a
10:40:70 14.3 (14.1–14.5) 12.5 (3.3–18.7) 18.0 (13.6–22.3)
30:150:200 10.8 (8.7–17.0) 12.4 (9.1–16.6) 14.6 (14.3–15.0)
Trough concentration (mg/mL) 3.1 (1.7–7.7) 4.0 (2.3–10.0) 9.5 (6.7–10.2)b
2 h concentration (mg/mL) 5.7 (2.5–13.2) 5.6 (2.5–13.0) 12.6 (8.1–16.3)b
aValue represents a single observation.
bP,0.01 (Kruskal–Wallis test).
Nevirapine levels in HIV-infected children
1357
JAC
reported that adult FDCs were not well suited to children, par-
ticularly at younger ages, while L’homme et al.6 observed that
certain paediatric formulations (Triomune baby and junior)
were appropriate for children weighing ≥6 kg. Mulenga et al.13
indicated that blood concentrations may be lower in infants
weighing 3–6 kg taking paediatric FDCs. While we confirmed
the vulnerability of children ≤3 years to being dosed inade-
quately, in our study, the formulation type did not influence
drug levels, though we did not have enough children weighing
,6 kg to test this sub-group properly.13
The weight-based dosing card developed by NACO4 is based on
the dosing schedule recommended by the WHO. However, about
half of the patients in this study were receiving less than the
minimum recommended dose of 300 mg/m2/day. The mean nevir-
apine doses received by the children in the present study were 290,
269 and 357 mg/m2/day for the 50, 70 and 200 mg nevirapine for-
mulations, respectively. While the 50 mg (paediatric) and 200 mg
(adult) combinations resulted in doses closer to the recommended
range, the 70 mg formulation resulted in the lowest doses received
by the children. However, we did not observe any difference in
plasma concentrations of nevirapine among children receiving the
different formulations, which limits us from drawing any firm con-
clusions about the unsuitability of that combination. Several
generic manufacturers now produce paediatric three-drug FDCs:
two combinations are available in India (stavudine, lamivudine
and nevirapine in the ratios 1:5:8 and 1:4:7). From the studies of
Poerksen et al.12 and Pollock et al.14 and the present study, it
appears that both the baby and adult formulations would result
in adequate dosing in children .3 years of age.
In our study, although stunted children had lower 2 h nevirapine
concentrations, the clinical significance of this is unclear, since we
were not able to determine virological outcomes in all cases. Ellis
et al.5 found that stunted children in Malawi and Zambia had
lower nevirapine concentrations, while wasted children tended to
have higher concentrations. A similar trend emerged from our logis-
tic regression analysis with stunting and wasting influencing nevir-
apine levels in opposite directions; however, neither was significant
after adjusting for other variables. It is known that pathophysiologi-
cal changes in the gut, liver and kidneys associated with malnu-
trition can alter pharmacokinetic processes, but the exact
mechanisms involved are unclear.15 Stunting is a chronic condition
and is associated with gut mucosal changes that could cause
malabsorption of drugs and altered levels of drug-metabolizing
enzymes in the liver leading to enhanced clearance and a decrease
in serum concentrations of protein-bound drugs. Wasting, being an
acute condition, could possibly lead to fatty liver, causing a reduced
rate of hepatic metabolism and an increase in plasma concen-
trations of drugs. The impact of malnutrition on antiretroviral
drug levels and its role in drug pharmacokinetics and response to
treatment deserves further study, since a large proportion of chil-
dren initiating treatment in resource-poor settings are malnour-
ished, and this is likely to be an important risk factor.16 Pollock
et al.14 studied the pharmacokinetics of nevirapine in HIV-infected
children and found that while nevirapine exposure was strongly
related to dose administered and age, malnutrition did not have
any effect.
The finding of higher nevirapine concentrations in children
with the TT genotype of CYP2B6 516G.T compared with those
with GG or GT is consistent with the observations of Saitoh
et al.17 While pharmaco-genotypes could be determined in
only a small subset of children in this study, it is likely to be an
important determinant of nevirapine concentrations. We and
others have shown that adults with the TT mutant genotype
have significantly higher concentrations of nevirapine than indi-
viduals with the GG or GT genotype.17 – 19
Ultimately, what is important are patient outcomes and
response to treatment. Chokephaibulkit et al.20,21 have demon-
strated the effectiveness of adult FDCs in treating HIV-infected
children, with appropriate nevirapine exposure and satisfactory
virological and immunological responses. In the present study,
while the majority of children initiating ART showed good
short-term clinical and immunological response, our finding of
detectable viraemia in 4 of 10 children among those with
sub-therapeutic nevirapine levels, after 6 months of ART, is wor-
rying and indicative of either suboptimal efficacy or suboptimal
adherence. All the children recruited in this study were receiving
treatment at government ART centres with no specific measures
to monitor adherence. However, self-adherence as reported by
care-givers was .90%. The possibility of sub-therapeutic nevira-
pine concentrations leading to development of viral resistance in
the long term cannot be ruled out.
Our study had some limitations. Viral load values were avail-
able in only a small number of children; therefore correlation
with treatment response could not be studied. Burger et al.22
recently demonstrated that a limited sampling model using
three timepoints (1, 2 and 6 h) could be used to predict nevirapine,
stavudine and lamivudine AUC accurately and precisely in
HIV-infected children. However, due to practical considerations,
blood sampling was limited to only two timepoints in our study
and the 2 h timepoint was chosen based on adult pharmacoki-
netic data.23 Further, our cohort was treated using one of three
different formulations, adding to the heterogeneity of the popu-
lation studied. Finally, pharmacogenetic testing was possible
only in 28 children due to limited availability of blood
specimens—this limited the power of our analysis as this factor
is likely to be an important determinant of non-nucleoside
reverse transcriptase inhibitor drug levels.
To our knowledge, this is the first study to evaluate the blood
concentrations of nevirapine in an Indian paediatric population
receiving treatment with generic paediatric antiretroviral drugs at
government ART centres. We found that the main factor affecting
nevirapine blood concentrations was age, with pharmacogenetics
and possibly nutritional status also contributing. A combination of
factors (younger age, stunting, CYP2B6 GG or GT genotype) could
potentially result in sub-therapeutic nevirapine concentrations in
some children. The study findings have important clinical impli-
cations and raise the issue of whether higher dose recommen-
dations are required for malnourished children and those
≤3 years old. With the recent revision in guidelines to initiate treat-
ment in infancy as soon as diagnosis of HIV has been made, dosing
of nevirapine in the very young child is a priority issue.2 A prospective
study on a large number of children receiving generic drugs is
required to correlate drug levels with treatment outcomes.
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